Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 5
2013 5
2014 3
2015 5
2016 9
2017 3
2018 8
2019 17
2020 10
2021 18
2022 11
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Restricted Net Treatment Benefit in oncology.
Piffoux M, Ozenne B, De Backer M, Buyse M, Chiem JC, Péron J. Piffoux M, et al. Among authors: peron j. J Clin Epidemiol. 2024 Apr 1;170:111340. doi: 10.1016/j.jclinepi.2024.111340. Online ahead of print. J Clin Epidemiol. 2024. PMID: 38570079
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study.
Trecourt A, Bakrin N, Glehen O, Gertych W, Villeneuve L, Isaac S, Benzerdjeb N, Fontaine J, Genestie C, Dartigues P, Leroux A, Quenet F, Marchal F, Odin C, Khellaf L, Svrcek M, Thierry S, Augros M, Omar A, Devouassoux-Shisheboran M, Kepenekian V; RENAPE Group. Trecourt A, et al. Ann Surg Oncol. 2024 May;31(5):3325-3338. doi: 10.1245/s10434-023-14850-0. Epub 2024 Feb 10. Ann Surg Oncol. 2024. PMID: 38341381 Free PMC article.
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A. Corbaux P, et al. Among authors: peron j. Eur J Cancer. 2023 Sep;191:112966. doi: 10.1016/j.ejca.2023.112966. Epub 2023 Jul 4. Eur J Cancer. 2023. PMID: 37542936 Free article.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy.
Lequesne J, Joly F, Peron J, Ray-Coquard I, Hardy-Bessard AC, Selle F, Berton D, Follana P, Fabbro M, Lortholary A, Pujade-Lauraine E, Lefèvre-Arbogast S, Coquan E. Lequesne J, et al. Among authors: peron j. J Natl Compr Canc Netw. 2023 May;21(5):473-479.e4. doi: 10.6004/jnccn.2022.7101. J Natl Compr Canc Netw. 2023. PMID: 37156482
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, Fontaine J, Péron J, Maillet D, Tartas S, Bonnin N, Trillet-Lenoir V, Colomban O, Augu-Denechere D, Freyer G, Tod M. Puszkiel A, et al. Among authors: peron j. Cancer Chemother Pharmacol. 2023 May;91(5):413-425. doi: 10.1007/s00280-023-04520-z. Epub 2023 Apr 3. Cancer Chemother Pharmacol. 2023. PMID: 37010549 Clinical Trial.
ASO Author Reflections: Colorectal Cancer Patients with Peritoneal Metastases and Other Metastatic Sites Can Benefit from Radical Multifocal Treatment After Comprehensive Evaluation for Accurate Selection.
Kepenekian V, Kefleyesus A, Passot G, Rousset P, Péron J, Glehen O. Kepenekian V, et al. Among authors: peron j. Ann Surg Oncol. 2023 Jul;30(7):4455-4456. doi: 10.1245/s10434-023-13320-x. Epub 2023 Mar 12. Ann Surg Oncol. 2023. PMID: 36907959 No abstract available.
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, Guitton J, Schwiertz V, Fontaine J, Peron J, Maillet D, Tartas S, Bonnin N, Colomban O, Augu-Denechere D, Freyer G, You B. Varnier R, et al. Among authors: peron j. Cancer Chemother Pharmacol. 2023 May;91(5):361-373. doi: 10.1007/s00280-023-04508-9. Epub 2023 Feb 25. Cancer Chemother Pharmacol. 2023. PMID: 36840749 Clinical Trial.
95 results